Improving P. Aeruginosa Detection With Breath-based Diagnostics (IMPACT-Breath)

Status: Recruiting
Location: See all (7) locations...
Study Type: Observational
SUMMARY

The study is a breath biomarker validation study. It is anticipated that 300 patients with cystic fibrosis (CF) from 5 clinical sites in the USA will be enrolled. The study is funded by the US NIH and the US Cystic Fibrosis Foundation. Enrollment commenced in May 2019. Sputum, induced sputum, and oropharyngeal swabs will be collected and evaluated at each clinic as part of standard clinical practice. Excess sputum will be sent to Children's Colorado Hospital for molecular analysis. No swabs will be sent anywhere (other than the clinic from which they originate). Breath samples will be taken from all study participants.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 3
Healthy Volunteers: f
View:

• Aim 1, Cross-Sectional

• IInclusion Criteria:

⁃ Male or female, ages 8 years and older

⁃ Diagnosis of CF based on sweat chloride ≥ 60 mmol/L and/or 2 known CF mutations

⁃ @ BC Children's Hospital only- Non-expectorators are eligible if having a clinically indicated OP swab.

⁃ FEV1 ≥ 30% predicted for spontaneous expectorators or FEV1 ≥ 40% predicted for subjects undergoing sputum induction

⁃ Either P. aeruginosa (Pa) negative or chronically infected with P. aeruginosa (Pa positive) as defined below:

⁃ a. P. aeruginosa negative: must meet one of the following criteria: i: No growth of Pa in previous 12 months and ≥ 4 consecutive Pa-negative cultures, OR ii: No history of Pa positive airway cultures (sputum, OP, Bronchoalveolar lavage) b. P. aeruginosa positive i: Over 50% of cultures positive and at least 2 cultures positive for Pa in previous 18 months

⁃ Willing to participate in and comply with the study procedures and willingness of the subject, parent or legally authorized representative to provide written informed consent.

⁃ Male or female, ages 8-16 years

⁃ Diagnosis of CF based on sweat chloride ≥ 60 mmol/L and/or 2 known CF mutations

⁃ @ BC Children's Hospital only- Non-expectorators are eligible if having a clinically indicated OP swab.

⁃ FEV1 ≥ 30% predicted for spontaneous expectorators or FEV1 ≥ 40% predicted for subjects undergoing sputum induction

⁃ P. aeruginosa negative, based on one of the following criteria:

∙ No growth of Pa in previous 12 months and ≥ 4 consecutive Pa-negative cultures

‣ No history of Pa positive airway cultures (sputum, OP, bronchoalveolar lavage)

⁃ Willing to participate in and comply with the study procedures and willingness of the subject, parent or legally authorized representative to provide written informed consent.

⁃ Male or female, ages 3-8 years

⁃ Diagnosis of CF based on sweat chloride ≥ 60 mmol/L and/or 2 known CF mutations 3. FEV1 ≥ 30%

• 4\. Unable to expectorate sputum 5. P. aeruginosa negative, based on one of the following criteria:

⁃ No growth of Pa in previous 12 months and ≥ 4 consecutive Pa-negative cultures

⁃ No history of Pa positive airway cultures (sputum, OP, bronchoalveolar lavage) 6. Willing to participate in and comply with the study procedures and willingness of the subject, parent or legally authorized representative to provide written informed consent.

Locations
United States
Arizona
Phoenix Children's Hospital
COMPLETED
Phoenix
Colorado
Children's Hospital Colorado
COMPLETED
Aurora
National Jewish Health
COMPLETED
Denver
New Hampshire
Dartmouth-Hitchcock Medical Center
NOT_YET_RECRUITING
Lebanon
Ohio
Cincinnati Children's Hospital
COMPLETED
Cincinnati
Other Locations
Canada
BC Children's Hospital
RECRUITING
Vancouver
St. Paul's Hospital
RECRUITING
Vancouver
Contact Information
Primary
Jane E Hill, PhD
jane.hill@ubc.ca
778 879 5105
Backup
Nina Nouribakikomarolya, PhD
nina.Nouribakikomarolya@ubc.ca
778 325 5038
Time Frame
Start Date: 2019-05-03
Estimated Completion Date: 2024-12-31
Participants
Target number of participants: 300
Treatments
AIM 1
No-Intervention. Participants in this group will have 1 study visit only. During that visit, breath and sputum samples will be collected.
AIM 2
No-Intervention. Participants in this group will have up to 8 study visits over a 2 year period. During the study visits, breath and sputum samples will be collected.
Related Therapeutic Areas
Sponsors
Collaborators: Arizona State University, Children's Hospital Colorado, Cystic Fibrosis Foundation, National Heart, Lung, and Blood Institute (NHLBI)
Leads: University of British Columbia

This content was sourced from clinicaltrials.gov